dc.contributor.author | Agapova, Maria | |
dc.contributor.author | Duignan, Andrea | |
dc.contributor.author | Smith, Alan | |
dc.contributor.author | O’Neill, Ciaran | |
dc.contributor.author | Basu, Anirban | |
dc.date.accessioned | 2018-09-20T15:59:00Z | |
dc.date.available | 2018-09-20T15:59:00Z | |
dc.date.issued | 2015-09-17 | |
dc.identifier.citation | Agapova, Maria; Duignan, Andrea; Smith, Alan; O’Neill, Ciaran; Basu, Anirban (2015). Long-term costs of introducing hpv-dna post-treatment surveillance to national cervical cancer screening in ireland. Expert Review of Pharmacoeconomics & Outcomes Research 15 (6), 999-1005 | |
dc.identifier.issn | 1473-7167,1744-8379 | |
dc.identifier.uri | http://hdl.handle.net/10379/10127 | |
dc.description.abstract | Introduction: Co-testing (cytology plus human papillomavirus DNA testing) as part of cervical cancer surveillance in Ireland increases one-time testing costs. Of interest to policy makers was the long-term impact of these costs accompanied by decreases in intensity of recalls for women with no detected abnormalities. Methods: A cost analysis of cytology-only and co-testing strategy was implemented using decision analytic modeling, aggregating testing utilization and costs for each of the two strategies over 12 years. Results: Aggregated incremental costs of the co-testing strategy were positive for the first 3 years but became negative thereafter, generating a cost savings of roughly Euro20 million in favor of the cytology-only strategy over a 12-year period. Results were robust over a range of sensitivity analyses with respect to discount and attrition rates. Discussion: This analysis provided valuable information to policy makers contributing to the introduction of co-testing for post-treatment surveillance (PTS) in Ireland. | |
dc.publisher | Informa UK Limited | |
dc.relation.ispartof | Expert Review of Pharmacoeconomics & Outcomes Research | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Ireland | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ie/ | |
dc.subject | cervical cancer | |
dc.subject | colposcopy | |
dc.subject | costs analysis | |
dc.subject | decision analysis | |
dc.subject | human papillomavirus | |
dc.subject | post-treatment surveillance | |
dc.subject | screening | |
dc.subject | intraepithelial neoplasia | |
dc.subject | follow-up | |
dc.subject | risk | |
dc.subject | women | |
dc.subject | netherlands | |
dc.subject | guidelines | |
dc.subject | cytology | |
dc.subject | disease | |
dc.subject | cohort | |
dc.subject | cure | |
dc.title | Long-term costs of introducing hpv-dna post-treatment surveillance to national cervical cancer screening in ireland | |
dc.type | Article | |
dc.identifier.doi | 10.1586/14737167.2015.1057126 | |
dc.local.publishedsource | http://europepmc.org/articles/pmc5902188?pdf=render | |
nui.item.downloads | 0 | |